Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Reata Pharma (NQ: RETA ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Reata Pharma < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference March 06, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire REATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA March 03, 2023 From Kahn Swick & Foti, LLC Via Business Wire Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review March 03, 2023 Many leaders flashed buy signals as the indexes rebounded from support. Via Investor's Business Daily Why Reata Pharmaceuticals Stock Skyrocketed This Week March 02, 2023 A major regulatory approval lit a fire underneath Reata's shares this week. Via The Motley Fool Why is OncoSec Medical (ONCS) Stock Up 91% Today? March 01, 2023 OncoSec Medical (ONCS) stock is rising higher with heavy trading on Wednesday after the company withdrew a public stock offering. Via InvestorPlace Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring, But Not Yet Talking About March 02, 2023 Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. Retail traders have countless methods at their disposal to uncover new information. For some, this... Via Benzinga Why Is Reata Pharmaceuticals Stock Trading Higher Today? March 01, 2023 Reata Pharmaceuticals (NASDAQ: RETA) shares are trading higher on Wednesday after the company announced the FDA approved SKYCLARYS for the treatment of Friedreich's ataxia. Via Benzinga Nasdaq Down 75 Points; B&G Foods Shares Spike Higher March 01, 2023 U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 75 points on Wednesday. The Dow traded down 0.19% to 32,596.21 while the NASDAQ fell 0.66% to 11,379. The... Via Benzinga Dow Looking To Rebound After Rocky February March 01, 2023 The Dow Jones Industrial Average is up 81 points this afternoon, while the S&P 500 Index and Nasdaq Composite are lower, with stocks kicking off a new month after a February decline. Via Talk Markets 12 Health Care Stocks Moving In Wednesday's Intraday Session March 01, 2023 Via Benzinga Why Reata Pharma Shares Are Skyrocketing Today March 01, 2023 Via Benzinga Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval February 28, 2023 The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys. Via Investor's Business Daily Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session March 01, 2023 Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. Via Benzinga Dow Edges Higher; ISM Manufacturing PMI Rises In February March 01, 2023 U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 30 points on Wednesday. The Dow traded up 0.12% to 32,695.97 while the NASDAQ fell 0.23% to 11,429.16. The S&P 500... Via Benzinga FDA Grants Approval of Reata Pharmaceuticals’ (NASDAQ: RETA) SKYCLARYS Drug, Making the First and Only Drug for Friedreich’s Ataxia March 01, 2023 Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization Via Spotlight Growth Exposures Product Safety 3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday March 01, 2023 U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. Via Benzinga US Stocks Edge Lower; Dollar Tree Profit Beats Views March 01, 2023 U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 30 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.09% to 32,626.82 while... Via Benzinga Reata Pharmaceuticals Gets Price Target Bumps By Analysts Following FDA Approval Of Skyclarys March 01, 2023 Reata Pharmaceuticals Inc (NASDAQ: RETA) reported the FDA approval of SKYCLARYS for patients with Friedreich's ataxia. With this approval, the FDA granted a rare pediatric disease priority review... Via Benzinga Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks March 01, 2023 Markets are trying to rise, and these companies are helping out. Via The Motley Fool Why Is Novavax (NVAX) Stock Down 26% Today? March 01, 2023 Novavax (NVAX) stock is dropping on Wednesday after the vaccine company warned investors about the state of its business. Via InvestorPlace Why Is OKYO Pharma (OKYO) Stock Down 31% Today? March 01, 2023 OKYO Pharma (OKYO) stock is taking a beating on Wednesday despite recent progress toward a Phase 2 clinical trial for dry eye treatment. Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 01, 2023 Via Benzinga Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket March 01, 2023 Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. Via Benzinga Why Is Reata Pharmaceuticals (RETA) Stock Up 175% Today? March 01, 2023 Reata Pharmaceuticals (RETA) stock is rocketing higher on Wednesday following approval from the FDA for one of its drugs. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday March 01, 2023 It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! Via InvestorPlace Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia February 28, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Reata Pharmaceuticals Unusual Options Activity For February 27 February 27, 2023 A whale with a lot of money to spend has taken a noticeably bearish stance on Reata Pharmaceuticals. Looking at options history for Reata Pharmaceuticals (NASDAQ:RETA) we detected 22 strange trades. Via Benzinga Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 27, 2023 Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test. Via Benzinga Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit February 27, 2023 The FDA is set to review the company's neurological drug by Tuesday. Via Investor's Business Daily Why Reata Pharmaceuticals Shares Are Falling Monday? February 27, 2023 According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.